GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Operating Margin %

Q32 Bio (Q32 Bio) Operating Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Q32 Bio's Operating Income for the three months ended in Mar. 2024 was $-14.84 Mil. Q32 Bio's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Q32 Bio's Operating Margin % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Q32 Bio's Operating Margin % or its related term are showing as below:

QTTB' s Operating Margin % Range Over the Past 10 Years
Min: -589.76   Med: 67.89   Max: 725.53
Current: 277.26


QTTB's Operating Margin % is ranked better than
99.42% of 1027 companies
in the Biotechnology industry
Industry Median: -166.59 vs QTTB: 277.26

Q32 Bio's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Q32 Bio's Operating Income for the three months ended in Mar. 2024 was $-14.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-40.65 Mil.


Q32 Bio Operating Margin % Historical Data

The historical data trend for Q32 Bio's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Operating Margin % Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
Operating Margin %
- -589.76 725.53

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial -209.29 -250.19 - 176.03 -

Competitive Comparison of Q32 Bio's Operating Margin %

For the Biotechnology subindustry, Q32 Bio's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Operating Margin % falls into.



Q32 Bio Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Q32 Bio's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-48.255 / -6.651
=725.53 %

Q32 Bio's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-14.843 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Q32 Bio  (NAS:QTTB) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Q32 Bio Operating Margin % Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Q32 Bio (Q32 Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus